Chemours Co is trading 5.2% up now at $21.37 after a U.S. federal appeals court vacated a preliminary injunction that had restricted parts of its business.
- The ruling, issued on June 8, removes a major legal overhang that had previously constrained the company's operational flexibility.
- The stock is extending its multi-day rebound as investors reassess regulatory and operational risks in light of the favorable court decision.